PL3368046T3 - Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania - Google Patents

Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Info

Publication number
PL3368046T3
PL3368046T3 PL16859111.3T PL16859111T PL3368046T3 PL 3368046 T3 PL3368046 T3 PL 3368046T3 PL 16859111 T PL16859111 T PL 16859111T PL 3368046 T3 PL3368046 T3 PL 3368046T3
Authority
PL
Poland
Prior art keywords
behaviour
brain function
synthetic composition
modulating brain
modulating
Prior art date
Application number
PL16859111.3T
Other languages
English (en)
Inventor
Bruce Mcconnell
Emma ELISON
Louise Kristine VIGSNÆS
Original Assignee
Glycom A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom A/S filed Critical Glycom A/S
Publication of PL3368046T3 publication Critical patent/PL3368046T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16859111.3T 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania PL3368046T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570696 2015-10-28
DKPA201670100 2016-02-24
PCT/DK2016/050344 WO2017071715A1 (en) 2015-10-28 2016-10-28 Synthetic composition and method for modulating brain function and behaviour

Publications (1)

Publication Number Publication Date
PL3368046T3 true PL3368046T3 (pl) 2022-11-28

Family

ID=58629784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16859111.3T PL3368046T3 (pl) 2015-10-28 2016-10-28 Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania

Country Status (7)

Country Link
US (2) US10835545B2 (pl)
EP (1) EP3368046B1 (pl)
CN (1) CN108348535B (pl)
DK (1) DK3368046T3 (pl)
ES (1) ES2927009T3 (pl)
PL (1) PL3368046T3 (pl)
WO (1) WO2017071715A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2924137T3 (es) * 2016-05-05 2022-10-04 Glycom As Composición que comprende HMOS para uso en el tratamiento de la hipersensibilidad y/o dolor visceral mediados por mastocitos
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
EP3634429A4 (en) 2017-05-09 2020-11-04 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
WO2018215960A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising one or more human milk oligosaccharides (hmos)
CN111526879A (zh) * 2017-11-02 2020-08-11 格礼卡姆股份公司 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
KR20190130720A (ko) * 2018-05-15 2019-11-25 (주)에이피테크놀로지 2'-푸코실락토오스를 포함하는 뇌졸중 예방용 조성물
WO2020128945A1 (en) * 2018-12-19 2020-06-25 Glycom A/S Separation of oligosaccharides
CA3161861A1 (en) * 2019-11-27 2021-06-03 Glycom A/S Mixture of hmos
AU2020399200A1 (en) * 2019-12-11 2022-06-09 Société des Produits Nestlé S.A. Compositions for use in the reduction of nociception and other health benefits in infants and young children
AU2019479118B2 (en) * 2019-12-19 2023-09-28 Hill's Pet Nutrition, Inc. Compositions and methods of treating and reducing risk of conditions associated with elevated 4-ethylphenyl sulfate
EP4255444A4 (en) * 2020-12-04 2024-10-16 Glycom A/S Human milk oligosaccharides for use in supporting maturation or improvement of sleeping patterns
US20250213600A1 (en) * 2022-03-18 2025-07-03 Meiji Co., Ltd. Composition for controlling growth of bacteria in the intestinal tract and use thereof
EP4536241A1 (en) 2022-06-09 2025-04-16 Société des Produits Nestlé S.A. Nutritional composition comprising gos and hmos

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796082B1 (fr) 1999-07-07 2003-06-27 Centre Nat Rech Scient Procede de production d'oligosaccharides
WO2007101862A1 (en) 2006-03-09 2007-09-13 Centre National De La Recherche Scientifique (Cnrs) Method of producing sialylated oligosaccharides
CN102459294A (zh) 2009-04-07 2012-05-16 格礼卡姆股份公司 2’-o-岩藻糖基乳糖的合成
ES2651067T3 (es) * 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
TR201807143T4 (tr) * 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
EP3241836B1 (en) 2010-02-19 2024-10-30 Glycom A/S Polymorph of a tetrasaccharide containing nacetyl-lactosamine
AU2011278236A1 (en) 2010-07-16 2013-02-07 Glycom A/S Derivatization of oligosaccharides
MX2013007736A (es) * 2010-12-29 2013-07-24 Nestec Sa Una composicion nutricional que comprende fibra y probioticos para reducir sintomas intestinales relacionados con estres.
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
PT2672844E (pt) 2011-02-10 2015-02-04 Nestec Sa Modulação do crescimento de bifidobactérias utilizando uma combinação de oligossacáridos identificados no leite humano
WO2012113404A1 (en) 2011-02-21 2012-08-30 Glycom A/S Novel glycosyl phosphites
CN103443113A (zh) 2011-03-18 2013-12-11 格力康公司 新型含岩藻糖的糖类衍生物的合成
CN103562214B9 (zh) 2011-05-13 2016-12-14 格力康公司 人乳寡糖(hmo)或其前体的多样化
WO2012155916A1 (en) 2011-05-13 2012-11-22 Glycom A/S Manufacture of lacto-n-tetraose
CN103562401A (zh) 2011-05-13 2014-02-05 格力康公司 产生人乳寡糖(hmo)或其前体的方法
HK1199607A1 (en) * 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP2760875A4 (en) 2011-09-30 2015-08-26 Glycom As SYNTHESIS OF HMO NUCLEAR STRUCTURES
WO2013091660A1 (en) 2011-12-23 2013-06-27 Glycom A/S A method for obtaining crystalline lacto-n-tetraose and lacto-n-neotetraose precursors and mixtures thereof
WO2013139344A1 (en) 2012-03-20 2013-09-26 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
CN104507483A (zh) * 2012-04-13 2015-04-08 波士顿学院理事会 益生元组合物及使用方法
WO2013161820A1 (ja) 2012-04-23 2013-10-31 国立大学法人京都大学 ビフィズス菌の増殖促進用組成物
ES2572831T3 (es) * 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
DK2708147T3 (da) 2012-09-14 2020-05-18 Abbott Lab Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
CA2893217C (en) * 2012-12-18 2017-11-28 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
CN104955344A (zh) 2012-12-18 2015-09-30 雅培制药有限公司 包含神经保护膳食寡糖的营养组合物
CN105518685A (zh) 2013-03-12 2016-04-20 雀巢产品技术援助有限公司 用于为罹患抑郁症的个体选择治疗方案的测定和方法
HK1231398A1 (zh) * 2014-04-08 2017-12-22 Abbott Laboratories 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
US20150305384A1 (en) 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160243139A1 (en) 2014-10-29 2016-08-25 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040050B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US20160287637A1 (en) 2014-12-08 2016-10-06 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10780103B2 (en) * 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
WO2017144062A1 (en) * 2016-02-24 2017-08-31 Glycom A/S Synthetic composition for microbiota modulation
US11224605B2 (en) * 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
WO2018157900A1 (en) * 2017-03-01 2018-09-07 Glycom A/S Synthetic composition for microbiota modulation
US11602545B2 (en) * 2017-12-05 2023-03-14 Glycom A/S Human milk oligosaccharides for treating migraine

Also Published As

Publication number Publication date
WO2017071715A1 (en) 2017-05-04
CN108348535B (zh) 2021-08-31
EP3368046A4 (en) 2019-07-03
US20180369260A1 (en) 2018-12-27
US11684630B2 (en) 2023-06-27
US20210077513A1 (en) 2021-03-18
CN108348535A (zh) 2018-07-31
ES2927009T3 (es) 2022-10-31
EP3368046A1 (en) 2018-09-05
DK3368046T3 (da) 2022-10-31
US10835545B2 (en) 2020-11-17
EP3368046B1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
IL286669A (en) Compounds and methods for modulating tmprss6 expression
PL3368046T3 (pl) Syntetyczna kompozycja i sposób modulowania funkcji mózgu i zachowania
IL285229A (en) Compounds and methods for modulating RNA function
IL271659A (en) Compositions and methods for modulating expression of complement factor B
ZA201801600B (en) Compounds and methods for modulating angiotensinogen expression
IL254780B (en) Electro-optical modulator
GB201512283D0 (en) Track behaviour events
IL247389A0 (en) Methods and preparations for personal pain management
HUE042875T2 (hu) Rendszerek és eljárások modulációs és kódolási séma választásra és konfigurálásra
PT3353303T (pt) Composições e métodos para modulação da expressão de ataxina 3
EP3193865A4 (en) Methods for treating brain metastasis
GB201504222D0 (en) Droplet assemblies and methods for producing droplet assemblies
GB201611699D0 (en) Behaviour modification
IL254197A0 (en) Methods to modulate bone density
SG11201705265RA (en) Composition for forming underlayer and method for forming underlayer therewith
GB201509420D0 (en) Composition and method
GB201513492D0 (en) Method and composition
GB201401612D0 (en) Synthetic method
PL3650431T3 (pl) Kompozycja zawierająca C<sub>8</sub>F<sub>17</sub>Br i sposób wytwarzania C<sub>8</sub>F<sub>17</sub>Br
ZA201803467B (en) Management method
SMT202100435T1 (it) Metodo di trattamento cosmetico
GB201712304D0 (en) Synthetic methods
GB201621716D0 (en) Composition and method for bone regeneration
GB201601185D0 (en) Method and composition
AU2015902928A0 (en) New synthetic methods